John-Joseph Borg

Purification of Human CD34+CD90+ HSCs Reduces Target Cell Population and Improves Lentiviral Transduction for Gene Therapy

Superior In vivo Transduction of Human Hepatocytes Using Engineered AAV3 Capsid

Cancer nanomedicine: progress, challenges and opportunities

21st century pharmacovigilance: efforts, roles, and responsibilities

Cancer-associated cachexia

Gene therapy returns to centre stage

Selective In Vivo Targeting of Human Liver Tumors by Optimized AAV3 Vectors in a Murine Xenograft Model

Safe and Effective In Vivo Targeting and Gene Editing in Hematopoietic Stem Cells: Strategies for Accelerating Development

Molecular Docking: Challenges, Advances and its Use in Drug Discovery Perspective

Practical multimodal care for cancer cachexia

Regulatory evaluation of Glybera in Europe — two committees, one mission

Multimodal management as requirement for the clinical use of anticachexia drugs - a regulatory and a clinical perspective

Strengthening and Rationalizing Pharmacovigilance in the EU: Where is Europe Heading to?